
Fidelity MSCI Health Care Index ETF (FHLC)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn more- Previous Close
88.37 - Open
89.51 - Bid 88.54 x 20000
- Ask 88.56 x 300000
- Day's Range
88.35 - 90.05 - 52 Week Range
68.46 - 90.05 - Volume
410,257 - Avg. Volume
244,665 - Net Assets 3.54B
- NAV 88.53
- PE Ratio (TTM) 31.93
- Yield 1.25%
- YTD Daily Total Return 20.43%
- Beta (5Y Monthly) 0.57
- Expense Ratio (net) 0.08%
Performance Overview
View MoreTrailing returns as of 10/31/2026. Category is Health.
People Also Watch
Recent News
View MoreResearch Reports
View MoreBiogen Earnings: Apellis Products Boost Growth Ahead of Key Lupus Readout
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Raising rating to BUY
Biogen Inc. is a biotech company that develops, manufactures, and sells therapies for treating neurological and neurodegenerative diseases. The company is the market leader in MS drugs and launched the first approved treatments for SMA and AD. The company also sells products that treat plaque psoriasis, non-Hodgkin's lymphoma, lymphocytic leukemia, and rheumatoid arthritis. Current research continues on MS and has expanded to include neuroimmunology, ophthalmology, lupus, and other neuromuscular and movement disorders. Founded in 1978, the company is located in Cambridge, Massachusetts; employs 7,500 people; and is a component of the S&P 500.
Completes Warner Bros. Discovery acquisition and changes name
Skydance Corp. is a worldwide media entertainment company. Paramount Global merged into Skydance Media on August 7, 2025 and Warner Bros. Discovery merged into Skydance on October 6, 2026. The publicly held Class B shares trade under the ticker symbol SKYD and have no voting rights. An investor consortium led by the Ellison family and private-equity firm RedBird Capital Partners holds 100% of the voting rights in the company. Skydance produces and distributes television and cable programming over its direct-to-consumer streaming services, cable, and free-to-air networks, including the flagship CBS broadcast network; and feature films through theatrical distribution. The company's businesses and trademarks include Paramount, Warner Bros., HBO, studio operations, and television distribution assets.
Paramount: New Co-CEO Will Run Operations As Firm Gets Clearance To Close Warner Bros. Acquisition
Paramount Skydance operates in three global business segments: TV media, filmed entertainment, and direct to consumer. The TV media business includes television production studios and various broadcast and cable networks, including CBS, 15 owned CBS affiliates, Paramount, Nickelodeon, MTV, BET, and VH1. Filmed entertainment consists of multiple film studios, most importantly Paramount Pictures. The film studios produce and distribute movies that they license to movie theaters and other media outlets. Direct to consumer includes the Paramount+, Pluto TV, and BET+ streaming services. Much of the content on Paramount’s streaming platforms is created by the production studios housed within the firm’s other two business segments.




